Michael Oberholzer, Phd Email & Phone Number

San Diego, Ca, Us

San Diego, Ca, Us

Global Medical Affairs strategy lead for Emerging & Multiomic Clinical Next-Generation Sequencing Applications

San Diego, Ca, Us

•Led and developed a high-performing team of Product Managers•Drove the Infectious Disease surveillance and testing portfolio from business case to commercialization, employing both organic and inorganic strategies.•Launched / developed impactful genomic surveillance and testing applications, including COVID-19, tuberculosis drug resistance, viral surveillance, Antimicrobial Resistance, and microbiome.•Spearheaded Illumina’s cross-functional COVID-19 genomic surveillance response, generating over $350M in revenue from 2020-2023.

Chemotherapeutics in parasitic protozoans. Cell signaling and external sensing in the protozoan parasite Trypanosoma brucei (Sleeping Sickness). cAMP signaling and phosphodiesterases PDEs: role in parasite biology and drug targeting.

Marlborough, Ma, Us

•Member of the upstream Product Management team, overseeing NAAT IVD portfolio strategy for the Hologic Panther platform.•Developed and presented business cases for novel Hologic Panther assays targeting women’s health, STIs, and virology, including Vaginosis/Vaginitis, Zika (US FDA EUA), and HIV DBS sample type.•Guided product concept and development from marketing perspective, managing processes from business case to commercialization.•Launched Zika Virus NAAT diagnostic assay (under EUA) globally and created impactful marketing collateral to drive demand.

Poway, California, Us

•Developed and led a high-performing team managing a portfolio of lateral flow rapid tests.•Directed organic and inorganic portfolio strategy for POCTs in Infectious Disease.•Launched POCT applications in Infectious Disease, creating impactful launch collateral and marketing strategies to drive demand.•Oversaw clinical performance studies for POCTs to support product registrations.•Coordinated external IVD product evaluations with WHO, FIND Diagnostics, and Ministries of Health.•Led marketing for programs including TORCH infections (Toxoplasma, Rubella, CMV, HSV), Rheumatic Arthritis Test, viral antigen and antibody tests (HIV, Dengue, Chikungunya), and tropical parasite antigen tests (Malaria, GI tract infections, Visceral Leishmania, Chagas).•Partnered with leading institutes and KOLs to develop novel biomarkers for Infectious Disease lateral flow diagnostics.

Los Angeles, Ca, Us

Identification of novel potential drug targets and biomarkers for the protozoan parasite Trypanosoma brucei (African Sleeping Sickness) using proteomic and trancriptomic approaches as well as FRET-based reporter assays and mouse in vivo infection models. In vitro and in vivo validation of newly identified potential drug targets for African Sleeping Sickness using genetic engineering of microbes, RNA interference, life cell imaging and transcriptomics.

La Jolla, Ca, Us

Identification of novel components of the Retinoblastoma (Rb) tumor suppressor pathway using single cell models systems and proteomics approaches. Development of small molecular library screens to identify modifiers of the Rb tumor suppressor pathway.

La Jolla, Ca, Us

Molecular mechanisms of cell signaling during cell migration and chemotaxis.

Phd, Microbiology

Education record

Master Of Science Msc, Microbiology

Bachelor Of Science - Bs, Biology